gerolama condorelli

List of Publications by Year in Descending Order

75 papers	5,749 citations	40 h-index	75 g-index
78 ext. papers	6,307 ext. citations	8.2 avg, IF	5.01 L-index

#	Paper	IF	Citations
75	Identification of a novel RNA aptamer that selectively targets breast cancer exosomes. *Molecular Therapy - Nucleic Acids*, **2021**, 23, 982-994	10.7	8
74	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. *Journal of the American College of Cardiology*, **2021**, 77, 2667-2676	15.1	4
73	miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer. *Cancer Gene Therapy*, **2021**, 28, 413-426	5.4	5
72	Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. *Molecular Therapy - Nucleic Acids*, **2020**, 20, 176-185	10.7	12
71	The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. *Molecular Therapy - Nucleic Acids*, **2019**, 18, 99-109	10.7	22
70	The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	62
69	Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. *Cancers*, **2019**, 11,	6.6	20
68	Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives. *Genes*, **2018**, 9,	4.2	15
67	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. *Molecular Therapy - Nucleic Acids*, **2018**, 13, 334-346	10.7	31
66	miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. *Oncogene*, **2015**, 34, 3240-50	9.2	142
65	Contrast-induced acute kidney injury: potential new strategies. *Current Opinion in Nephrology and Hypertension*, **2015**, 24, 145-53	3.5	17
64	Arresting the colonial destiny of metastatic seeds with DNA aptamers. *Molecular Therapy*, **2015**, 23, 982-984	11.7	1
63	Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFR aptamer. *Molecular Therapy*, **2014**, 22, 828-41	11.7	90
62	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. *European Journal of Heart Failure*, **2014**, 16, 358-66	12.3	61
61	Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. *Journal of Cellular Physiology*, **2014**, 229, 1359-68	7	38
60	Multifunctional aptamer-miRNA conjugates for targeted cancer therapy. *Molecular Therapy*, **2014**, 22, 1151-1163	11.7	134
59	Hydration in contrast-induced acute kidney injury. *Lancet, The*, **2014**, 383, 1786-8	40	8

58	Correction for Romano et al., MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10389-10389	11.5	78
57	Novel biomarkers for contrast-induced acute kidney injury. *BioMed Research International*, **2014**, 2014, 568738	3	35
56	Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay. *Analytical and Bioanalytical Chemistry*, **2013**, 405, 1025-34	4.4	101
55	Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. *BMC Medical Genetics*, **2013**, 14, 11	2.1	21
54	Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. *Oncogene*, **2013**, 32, 4001-8	9.2	94
53	miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. *Oncogene*, **2013**, 32, 341-51	9.2	79
52	Therapeutic strategies to prevent contrast-induced acute kidney injury. *Current Opinion in Cardiology*, **2013**, 28, 676-82	2.1	14
51	Insulin-Activated Protein Kinase C□Bypasses Ras and Stimulates Mitogen-Activated Protein Kinase Activity and Cell Proliferation in Muscle Cells. *Molecular and Cellular Biology*, **2013**, 33, 1474-1474	4.8	78
50	Endothelial progenitor cells in coronary artery disease. *Biological Chemistry*, **2013**, 394, 1241-52	4.5	6
49	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. *PLoS ONE*, **2013**, 8, e74466	3.7	71
48	Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. *Circulation*, **2012**, 126, 3008-16	16.7	140
47	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. *Oncogene*, **2012**, 31, 634-42	9.2	160
46	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP□*Oncogene*, **2012**, 31, 858-68	9.2	146
45	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16570-5	11.5	142
44	EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. *Nature Medicine*, **2011**, 18, 74-82	50.5	328
43	Epigenetic regulation of miR-212 expression in lung cancer. *PLoS ONE*, **2011**, 6, e27722	3.7	64
42	"ApoptomiRs" in vascular cells: their role in physiological and pathological angiogenesis. *Vascular Pharmacology*, **2011**, 55, 87-91	5.9	15
41	Nephrotoxicity of contrast media and protective effects of acetylcysteine. *Archives of Toxicology*, **2011**, 85, 165-73	5.8	37

40	In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. *Cell Death and Disease*, **2011**, 2, e155	9.8	94
39	Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. *Circulation: Cardiovascular Interventions*, **2011**, 4, 121-9	6	33
38	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. *Circulation*, **2011**, 124, 1260-9	16.7	163
37	A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. *PLoS ONE*, **2011**, 6, e24071	3.7	113
36	Renal insufficiency following contrast media administration trial II (REMEDIAL II): RenalGuard system in high-risk patients for contrast-induced acute kidney injury: rationale and design. *EuroIntervention*, **2011**, 6, 1117-22, 7	3.1	18
35	MicroRNAs as regulators of death receptors signaling. *Cell Death and Differentiation*, **2010**, 17, 200-8	12.7	92
34	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. *FASEB Journal*, **2010**, 24, 1981-8	0.9	70
33	c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3 activity. *Cell Death and Differentiation*, **2010**, 17, 1908-16	12.7	26
32	miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. *Cancer Research*, **2010**, 70, 3638-46	10.1	122
31	PED interacts with Rac1 and regulates cell migration/invasion processes in human non-small cell lung cancer cells. *Journal of Cellular Physiology*, **2010**, 225, 63-72	7	15
30	Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. *Oncology*, **2009**, 77, 378-84	3.6	31
29	Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15). *Journal of Cellular and Molecular Medicine*, **2009**, 13, 3315-28	5.6	3
28	miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. *Cancer Cell*, **2009**, 16, 498-509	24.3	672
27	MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. *Oncogene*, **2008**, 27, 3845-55	5.5	236
26	Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. *Cell Death and Differentiation*, **2008**, 15, 762-72	12.7	162
25	PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 2416-26	5.6	35
24	MicroRNAs in diseases and drug response. *Current Opinion in Pharmacology*, **2008**, 8, 661-7	5.1	62
23	Contrast agents and renal cell apoptosis. *European Heart Journal*, **2008**, 29, 2569-76	9.5	154

22	Akt regulates drug-induced cell death through Bcl-w downregulation. *PLoS ONE*, **2008**, 3, e4070	3.7	15
21	Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. *International Journal of Cancer*, **2007**, 120, 1215-22	7.5	34
20	Shp2 in PC12 cells: NGF versus EGF signalling. *Cellular Signalling*, **2007**, 19, 1193-200	4.9	10
19	Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. *American Journal of Cardiology*, **2007**, 99, 779-84	3	71
18	Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. *American Journal of Cardiology*, **2006**, 97, 472-6	3	16
17	Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. *Cancer Research*, **2006**, 66, 1491-9	10.1	99
16	Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. *American Heart Journal*, **2005**, 150, 807-13	4.9	17
15	Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes. *Journal of the American College of Cardiology*, **2005**, 45, 464-6	15.1	18
14	Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. *Circulation Research*, **2005**, 96, 180-8	15.7	112
13	PED mediates AKT-dependent chemoresistance in human breast cancer cells. *Cancer Research*, **2005**, 65, 6668-75	10.1	53
12	Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. *Journal of Experimental Medicine*, **2004**, 200, 1257-66	16.6	91
11	Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. *Molecular and Cellular Biology*, **2003**, 23, 4511-21	4.8	125
10	TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. *FASEB Journal*, **2002**, 16, 1732-7	0.9	62
9	Multiple members of the mitogen-activated protein kinase family are necessary for PED/PEA-15 anti-apoptotic function. *Journal of Biological Chemistry*, **2002**, 277, 11013-8	5.4	47
8	Insulin-activated protein kinase Cbeta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells. *Molecular and Cellular Biology*, **2000**, 20, 6323-33	4.8	63
7	In L6 skeletal muscle cells, glucose induces cytosolic translocation of protein kinase C-alpha and trans-activates the insulin receptor kinase. *Journal of Biological Chemistry*, **1999**, 274, 28637-44	5.4	30
6	Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg1152 --> Gln insulin receptor. *Journal of Biological Chemistry*, **1999**, 274, 3094-102	5.4	30
5	PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. *Oncogene*, **1999**, 18, 4409-15	9.2	146

4	PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. *EMBO Journal*, **1998**, 17, 3858-66	13	136
3	In NIH-3T3 fibroblasts, insulin receptor interaction with specific protein kinase C isoforms controls receptor intracellular routing. *Journal of Biological Chemistry*, **1998**, 273, 13197-202	5.4	39
2	Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. *Journal of Biological Chemistry*, **1998**, 273, 4672-80	5.4	131
1	In skeletal muscle, glucose storage and oxidation are differentially impaired by the IR1152 mutant receptor. *Journal of Biological Chemistry*, **1997**, 272, 7290-7	5.4	23